S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Neurocrine Biosciences Stock Forecast, Price & News

+1.91 (+1.66 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $116.91
50-Day Range
MA: $100.39
52-Week Range
Now: $116.91
Volume647,929 shs
Average Volume1.00 million shs
Market Capitalization$10.92 billion
P/E Ratio125.71
Dividend YieldN/A
Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL Â- Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences logo


Overall MarketRank

1.89 out of 5 stars

Medical Sector

92nd out of 1,923 stocks

Biological Products, Except Diagnostic Industry

6th out of 177 stocks

Analyst Opinion: 2.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:NBIX



Sales & Book Value

Annual Sales$788.10 million
Cash Flow$0.74 per share
Book Value$6.92 per share


Net Income$37.01 million


Market Cap$10.92 billion
Next Earnings Date2/4/2021 (Confirmed)
+1.91 (+1.66 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

How has Neurocrine Biosciences' stock been impacted by Coronavirus?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NBIX stock has increased by 36.1% and is now trading at $116.91.
View which stocks have been most impacted by COVID-19

Is Neurocrine Biosciences a buy right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 8 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Neurocrine Biosciences stock.
View analyst ratings for Neurocrine Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Neurocrine Biosciences?

Wall Street analysts have given Neurocrine Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neurocrine Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Neurocrine Biosciences

How can I listen to Neurocrine Biosciences' earnings call?

Neurocrine Biosciences will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its quarterly earnings results on Saturday, November, 14th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.11 by $0.73. The business earned $258.80 million during the quarter, compared to analysts' expectations of $282.59 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 18.18% and a net margin of 8.96%. Neurocrine Biosciences's revenue was up 16.5% on a year-over-year basis. During the same quarter last year, the business posted $0.56 earnings per share.
View Neurocrine Biosciences' earnings history

What price target have analysts set for NBIX?

19 brokerages have issued twelve-month target prices for Neurocrine Biosciences' shares. Their forecasts range from $90.00 to $149.00. On average, they expect Neurocrine Biosciences' share price to reach $126.53 in the next year. This suggests a possible upside of 8.2% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences
or view Wall Street analyst' top-rated stocks.

Who are some of Neurocrine Biosciences' key competitors?

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), The Walt Disney (DIS), Tesla (TSLA), Square (SQ) and salesforce.com (CRM).

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:
  • Dr. Kevin C. Gorman, CEO & Director (Age 63, Pay $1.45M)
  • Mr. Matthew C. Abernethy, Chief Financial Officer (Age 41, Pay $822.74k)
  • Dr. Haig P. Bozigian, Chief Devel. Officer (Age 63, Pay $780.63k)
  • Mr. Eric S. Benevich, Chief Commercial Officer (Age 56, Pay $793.07k)
  • Ms. Eiry Wyn Roberts, Chief Medical Officer (Age 57, Pay $899.55k)
  • Dr. Dimitri E. Grigoriadis, Chief Research Officer (Age 63)
  • Jane Sorensen, Head of Investor Relations
  • Mr. Darin M. Lippoldt, Chief Legal Officer & Corp. Sec. (Age 55)
  • Mr. Kyle W. Gano, Chief Bus. Devel. and Strategy Officer (Age 48)
  • Ms. Julie Cooke, Chief HR Officer (Age 55)

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.25%), Candriam Luxembourg S.C.A. (0.17%), Rhenman & Partners Asset Management AB (0.16%), State of Alaska Department of Revenue (0.05%), DNB Asset Management AS (0.04%) and Polianta Ltd (0.01%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, NuWave Investment Management LLC, Scout Investments Inc., Highland Capital Management LLC, We Are One Seven LLC, Redpoint Investment Management Pty Ltd, and First Hawaiian Bank. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, and Stephen A Sherwin.
View insider buying and selling activity for Neurocrine Biosciences
or view top insider-selling stocks.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, DNB Asset Management AS, Candriam Luxembourg S.C.A., Cutler Group LP, Vigilare Wealth Management, Polianta Ltd, IFM Investors Pty Ltd, and OneAscent Financial Services LLC.
View insider buying and selling activity for Neurocrine Biosciences
or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $116.91.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $10.92 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 825 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.